Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.68 |
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.59 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19501816 | 0.94 | SIRT1 (0.70) | NPC1RAB9ALMNAKDM4EPTPN1 | |
| SCHEMBL2563194 | 0.93 | NPC1 (0.68) | NPC1RAB9ALMNAKDM4EPTPN1 | |
| SCHEMBL23844169 | 0.91 | LMNA (0.76) | NPC1RAB9ALMNAKDM4ESMN1; SMN2 | |
| SCHEMBL104759 | 0.90 | PTPN1 (0.68) | NPC1RAB9ALMNAKDM4EPTPN1 | |
| SCHEMBL19491379 | 0.89 | SIRT1 (0.72) | NPC1RAB9ALMNAKDM4ESMN1; SMN2 | |
| SCHEMBL8461727 | 0.88 | LMNA (0.68) | NPC1RAB9ALMNAKDM4ESMN1; SMN2 | |
| SCHEMBL26915306 | 0.88 | LMNA (0.68) | NPC1RAB9ALMNAKDM4ESMN1; SMN2 | |
| SCHEMBL14846601 | 0.86 | ROCK2 (0.72) | NPC1RAB9ALMNAKDM4EPTPN1 | |
| SCHEMBL297860 | 0.86 | NR1H4 (0.73) | NPC1RAB9ALMNAKDM4EPTPN1 | |
| SCHEMBL27859771 | 0.86 | HDAC2 (0.64) | NPC1RAB9ALMNAKDM4EPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110937987-B | Synthetic route of compound and application of compound in field of preparation of antidiabetic drugs | 深圳市灵兰生物医药科技有限公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-110937987-A | Synthetic route of compound and application of compound in field of preparation of antidiabetic drugs | 深圳市灵兰生物医药科技有限公司 | 2020-03-31 | — | — | CN | disclosed |
| US-10544092-B2 | Malononitrile oxime ether compound and use thereof | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2020-01-28 | — | — | US | disclosed |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| US-8921555-B2 | Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones | MERCK SHARP & DOHME CORP. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120095001-A1 | SUBSTITUTED-1,3,8-TRIAZASPIRO[4.5]DECANE-2,4-DIONES | MERCK SHARP & DOHME CORP. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20070141630-A1 | IDENTIFICATION OF NON-COVALENT COMPLEXES BY MASS SPECTROMETRY | GENENTECH, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070141630-A1 | IDENTIFICATION OF NON-COVALENT COMPLEXES BY MASS SPECTROMETRY | GENENTECH, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | NPC1 1892/4885RAB9A 3030/4885LMNA 3669/4885 |
| US-10544092-B2 | Malononitrile oxime ether compound and use thereof | ME1, MAL2, ME3 | NPC1 4630/4885RAB9A 4007/4885LMNA 4658/4885 |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LCK | NPC1 4487/4885RAB9A 2628/4885LMNA 4662/4885 |
| US-20120095001-A1 | SUBSTITUTED-1,3,8-TRIAZASPIRO[4.5]DECANE-2,4-DIONES | HIF1AN, HIF1A, EGLN2 | NPC1 3927/4885RAB9A 4576/4885LMNA 4005/4885 |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | NPC1 869/4885RAB9A 733/4885LMNA 2198/4885 |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | NPC1 1778/4885RAB9A 1841/4885LMNA 3170/4885 |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LCK | NPC1 4487/4885RAB9A 2628/4885LMNA 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.